{"schema_version":"secwatch.filing_event.v1","accession":"0001161697-22-000215","form_type":"8-K","ticker":"KRMD","cik":"0000704440","company_name":"KORU Medical Systems, Inc.","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.413628+00:00","generated_at":"2026-06-26T00:59:34.697318+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"KORU Medical Q1 net sales up 15% to $6.2M, net loss widens to $2.5M, raises FY22 revenue guidance","bullets":["Net sales $6.24M (+15% YoY); domestic core up 13.2%, novel therapies $0.36M (including NRE).","GAAP net loss $2.5M (-$0.06 EPS) vs $1.3M loss (-$0.03 EPS) prior year; adjusted EPS -$0.05.","Gross margin 58.0% (-150bps) on higher raw material/labor costs; operating expenses $6.7M (+24% YoY).","Raises FY22 revenue guidance to $26.5-$27.0M (prev $26.0-$27.0M); reaffirms 60% gross margin exit run rate."],"urls":{"canonical":"https://secwatch.observer/filing/0001161697-22-000215","json":"https://secwatch.observer/filing/0001161697-22-000215.json","markdown":"https://secwatch.observer/filing/0001161697-22-000215.md","text":"https://secwatch.observer/filing/0001161697-22-000215.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/704440/000116169722000215/0001161697-22-000215-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/704440/000116169722000215/form_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:59:34.697318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}